查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1736763

全球电子药物传输系统市场规模（按类型、适应症、区域覆盖范围和预测）

Global Electronic Drug Delivery Systems Market Size By Type (wearable infusion pumps, Autoinjectors, injection pens), By Indication(diabetes, multiple sclerosis, cardiovascular disease), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

电子药物传输系统市场规模及预测

电子药物输送系统市场规模预计在 2024 年达到 105.7 亿美元，到 2032 年将达到 192.6 亿美元，在 2026-2032 年预测期内的复合年增长率为 7.79%。

各种慢性病的高发生率，以及易患心血管和呼吸系统疾病的老年患者人数的不断增加，是预测期内推动市场需求的关键因素。电子药物输送系统市场报告对市场进行了全面的评估，包括关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的关键因素。

定义电子药物传输系统的全球市场

电子给药系统是一种智慧的、电子操作的给药设备，适用于居家医疗。这些设备为传统设备增添了价值，提高了给药的便利性、便利性和便携性。此外，这些系统在医院和其他临床环境中也具有宝贵的优势。电子给药系统可以加速糖尿病、心血管疾病和呼吸系统疾病等慢性疾病的管理。

目前，各种技术正在与计算工具相结合，以创新药物输送系统，例如电子药物输送系统。电子药物输送系统已为医疗专业人员、看护者和患者带来了许多益处，包括药物治疗。穿戴式输液帮浦、可注射胰岛素笔、电子自动注射器、电子吸入器等是市面上现有的一些电子药物输送系统。及时正确地註射胰岛素是糖尿病患者最关心的问题，而电子胰岛素笔可以帮助他们。

全球电子药物传输系统市场概况

市场的主要驱动因素包括糖尿病、气喘和心血管疾病等慢性疾病的日益流行，以及智慧给药系统技术的发展进步。与传统给药方式相比，电子给药系统具有许多优势，例如效率更高、耗时更少、副作用更小以及患者可自行给药，这些优势预计将推动全球市场的成长。电子给药系统确保药物在患者体内正确输送。电子给药系统有助于提醒患者註意服药习惯，并提供正确的用药指导。

输液帮浦新药配方的核准将推动成人糖尿病护理，带来新的治疗方案。此外，智慧型穿戴式输液帮浦可让患者无线连接到智慧型手机应用程序，使医疗保健专业人员能够追踪患者数据并根据个人需求制定个人化治疗方案。用于糖尿病管理的联网自动注射器的推出预计将推动市场成长。自动注射器和电子帮浦是慢性疾病患者用于小剂量给药的主要设备。上述因素正在推动全球对电子药物输送系统的需求。

然而，系统高成本、维护需求高、替代给药方式的可用性低以及低收入国家缺乏相关认知度，将限制全球电子给药系统市场的发展。此外，自动帮浦存在技术故障风险，可能导致剂量错误，进而引发药物不良反应。这可能会阻碍市场成长。技术进步带来了自主给药技术，主要是输液帮浦和自动注射器，这些技术适用于大容量和高黏度生技药品，为企业创造了潜在的市场机会。

目录

第一章电子药物传输系统全球市场介绍

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章电子药物传输系统的全球市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章全球电子药物传输系统市场（按类型）

  • 概述
  • 穿戴式输液泵
  • 自动注射器
  • 注射笔
  • 吸入器

6. 全球电子药物传输系统市场（按适应症）

  • 概述
  • 糖尿病
  • 多发性硬化症
  • 心血管疾病
  • 其他的

7. 全球电子药物传输系统市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 中东和非洲
    • 拉丁美洲

8. 全球电子药物传输系统市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第九章 公司简介

  • Gerresheimer AG
  • Amgen
  • Novo Nordisk
  • Bayer AG
  • Medtronic plc
  • Insulet Corporation
  • AstraZeneca
  • Tandem Diabetes Care
  • Merck Group
  • United Therapeutics Corporation

第十章 附录

  • 相关调查
简介目录
Product Code: 40792

Electronic Drug Delivery Systems Market Size And Forecast

Electronic Drug Delivery Systems Market size was valued at USD 10.57 Billion in 2024 and is projected to reach USD 19.26 Billion by 2032, growing at a CAGR of 7.79% from 2026 to 2032.

The high prevalence of various chronic disorders and increase in the geriatric patient pool susceptible to cardiovascular and respiratory diseases are the major drivers that propelled the market's demand in the forecast period. The Global Electronic Drug Delivery Systems Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Electronic Drug Delivery Systems Market Definition

These are electronically enabled, smart drug delivery devices are well suited to home care settings. These devices add value to traditional instruments and improve ease of administration, convenience, and portability. However, these systems offer valuable advantages within hospitals and other clinical settings. Electronic drug delivery systems rapidly manage chronic ailments, including diabetes, cardiovascular diseases, respiratory disorders, and other applications.

Nowadays, different technologies are being merged with computation tools to innovate drug delivery systems such as electronic drug delivery systems. It offers several benefits to patients, which include medical professionals, caregivers, and drug regimens. Wearable infusion pumps, injectable insulin pens, electronic autoinjectors, and electronic inhalers are some of the electronic drug delivery systems available in the market. Timely and appropriate insulin dosing are critical concerns in diabetes patients, and electronic insulin pens can help patients.

Global Electronic Drug Delivery Systems Market Overview

The market's significant factors include the increasing prevalence of chronic diseases, such as diabetes, asthma, cardiovascular disease, and technological advancements in developing smart drug delivery systems. Several advantages such as improved efficiency, lesser time consumption, minimum side effects, and self-administered therapy for patients offered by electronic drug delivery systems over conventional drug delivery methods are expected to boost the market's growth globally. Electronic drug delivery systems ensure whether the medications are correctly delivered to the patient's body or not. It helps remind the patients about their drugs intake routine and provides appropriate guidance on using their medications.

Approvals of novel drug formulations in infusion pumps allow a novel treatment option, advancing diabetes care in adults. Moreover, the smart wearable infusion pumps allow the patients to connect to smartphone apps wirelessly. This enables healthcare professionals to track patient data and tailor specific therapies as per individual requirements. The launch of connected autoinjectors for the management of diabetes is expected to drive market growth. Autoinjectors and electronic pumps are the primary devices used in chronic diseases to deliver smaller doses. The factors mentioned above have augmented the demand for electronic drug delivery systems globally.

However, the high cost of systems, the need for maintenance, the availability of alternative modes of drug delivery, and lack of awareness in low-income countries will restrict the global Electronic Drug Delivery Systems Market. In addition, automated pumps may have risks of the wrong dosage with technical glitches and might lead to adverse drug reactions. This may hinder the market growth. Technological advancements allow accessible self-administration technologies, mainly in infusion pumps and autoinjectors that help in large-volume and high-viscosity biologic drugs, which have created a potential market opportunity for the companies.

Global Electronic Drug Delivery Systems Market: Segmentation Analysis

The Global Electronic Drug Delivery Systems Market is Segmented on the basis of Type, Indication, and Geography.

Electronic Drug Delivery Systems Market, By Type

  • Wearable Infusion Pumps
  • Autoinjectors
  • Injection Pens
  • Inhalers

Based on Type, the market is bifurcated into wearable infusion pumps, autoinjectors, injection pens, and inhalers. Wearable infusion pumps hold the largest market share. The segment will retain its dominant position throughout the forecast period as these pumps are widely used for diabetes management. The injection pen segment is likely to register the fastest CAGR. The approval for injection pens to treat diabetes, offering a portable and convenient option, is expected to increase the segment's market share over the forecast period.

Electronic Drug Delivery Systems Market, By Indication

  • Diabetes
  • Multiple Sclerosis
  • Cardiovascular Disease
  • Others

Based on Indication, the market is bifurcated into diabetes, multiple sclerosis, cardiovascular disease, and others. The diabetes segment dominates the market due to the high prevalence rate of diabetes among other chronic diseases worldwide and rising adoption of smartphone apps, easy availability of devices like insulin pumps and injection pens by major market players by market players compared to other electronic drug delivery systems.

Electronic Drug Delivery Systems Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of regional analysis, the Global Electronic Drug Delivery Systems Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America. The increased incidence of target diseases, a rise in the patient population, favorable remuneration policies, and the launch of advanced Electronic Drug Delivery Systems by significant players are attributed to the increase in market revenue.

Key Players

The "Global Electronic Drug Delivery Systems Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Gerresheimer AG, Amgen, Novo Nordisk, Bayer AG, Medtronic plc, Insulet Corporation, AstraZeneca, Tandem Diabetes Care, Merck Group, and United Therapeutics Corporation.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porter Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Wearable Infusion Pumps
  • 5.3 Autoinjectors
  • 5.4 Injection Pens
  • 5.5 Inhalers

6 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET, BY INDICATION

  • 6.1 Overview
  • 6.2 Diabetes
  • 6.3 Multiple Sclerosis
  • 6.4 Cardiovascular Disease
  • 6.5 Others

7 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Middle East and Africa
    • 7.5.2 Latin America

8 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Gerresheimer AG
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Amgen
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Novo Nordisk
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Bayer AG
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Medtronic plc
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Insulet Corporation
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 AstraZeneca
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Tandem Diabetes Care
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Merck Group
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 United Therapeutics Corporation
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Appendix

  • 10.1 Related Research